The purpose of the liquidity provider is to improve the liquidity of the share and reduce the difference between the buying and selling price. The assignment commences on May 24, 2019.

Mangold will fulfill its assignment as liquidity provider to ensure the possibility of trading in Cereno Scientific’s share every day by continuously placing trading records on each purchase and sales page in the order book. A Liquidity provider aims to create a more accurate price picture in a company"s share, which in turn gives a more accurate valuation of the company and allows for an improved trading volume in the share.

For further information, please contact:
Daniel Brodén  – CFO
Tel: +46 768 66 77 87
E-mail: info@cerenoscientific.com
www.cerenoscientific.se

About Cereno Scientific AB 
Cereno Scientific is developing novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. In parallel with the development of CS1, Cereno Scientific develops CS014, a preclinical phase compound with promising and innovative characteristics in cardiovascular diseases. The Gothenburg-based company is located in AstraZeneca’s BioVenture Hub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.